Overview

Prophylactic Anti-Seizure Medication vs No Anti-Seizure Medication for Patients With Primary Motor Cortex Brain Metastases

Status:
NOT_YET_RECRUITING

Trial end date:
2030-02-01

Target enrollment:

Participant gender:

Summary

This is a randomized trial for patients with brain metastases in the primary motor cortex who have not had seizures to receive either the prophylactic anti-seizure medication levetiracetam (also known by its trade name Keppra) or proceed with standard of care management, which does not currently include prophylactic levetiracetam. Patients who enroll to this trial will be randomized to receive prophylactic levetiracetam or not receive prophylactic levetiracetam.

Phase:

PHASE2

Details

Lead Sponsor:

Ayal A. Aizer, MD

Treatments:

Levetiracetam